• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Abbott forecasts 2024 earnings largely below estimates, shares down

cafead

Administrator
Staff member
  • cafead   Jan 24, 2024 at 09:42: AM
via Abbott Laboratories on Wednesday forecast 2024 profit largely below Wall Street estimates despite meeting quarterly earnings expectations, sending the medical device maker's shares down 2.5% in premarket trading.

article source